Renaissance Capital logo

LogicBio Therapeutics Priced, Nasdaq: LOGC

Preclinical gene editing biotech developing therapies for rare diseases.

Industry: Health Care

First Day Return: +15.0%

We are a genome editing company focused on developing medicines to durably treat rare diseases in patients with significant unmet medical need using GeneRide, our proprietary technology platform. Our GeneRide technology is designed to precisely integrate corrective genes into a patient’s genome to provide a stable therapeutic effect. Because GeneRide is designed to have this durable therapeutic effect, we are initially targeting rare liver disorders in pediatric patients where it is critical to provide treatment early in a patient’s life before irreversible disease pathology can occur. We have demonstrated proof of concept of our therapeutic platform in animal models for a number of diseases and are focusing on development of our lead product candidate, LB-001, for the treatment of Methylmalonic Acidemia, or MMA, a life-threatening disease that presents at birth.

LogicBio Therapeutics (LOGC) Performance

Created with Highcharts 10.3.2Chart context menuLOGC vs. IPO Index (IPOUSA)Jan 2019May 2019Sep 2019Jan 2020May 2020Sep 2020Jan 2021May 2021Sep 2021Jan 2022May 2022Sep 2022Jan 2023May 2023Sep 2023Jan 2024May 2024Sep 2024Jan 2025May 20250%+ 100%+ 200%-100%View 5 days5dView 1 month1mView 3 months3mView year to dateYTDView 1 year1yView allAllRenaissance IPO IndexOur ETF tracks the IPO Index